Dr. Pier Vitale Nuzzo has been recognized for their outstanding work at the recent ESMO Targeted Anticancer Therapies Congress (TAT) 2024 in Paris (26-28 February 2024).
Dr. Nuzzo received two prestigious awards - the ESMO Merit Travel Grant and the ESMO TAT Award for Best Poster - with the abstract "Targeting de novo lipogenesis synergizes with androgen receptor inhibitors in castration-resistant prostate cancer".
Out of over 120 presentations, the ESMO TAT scientific committee acknowledged Dr. Nuzzo's work for the promising preliminary data and innovative design of a phase I clinical trial with the new Fatty acid synthase (FASN) inhibitor combined with Enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
The trial is currently underway at Weill Cornell Medicine (WCM) and is actively recruiting patients (NCT05743621).